This clinical study focuses on evaluating a new treatment for gastrointestinal neoplasms, which are cancers that develop in the digestive system. The study specifically looks at cases where the cancer is advanced and cannot be surgically removed (unresectable) or has spread to other parts of the body (metastatic). The investigational medication, called GSK5764227, will be tested both alone and in combination with other treatments.

The medication GSK5764227 is administered through intravenous infusion, which means it is given directly into a vein. The drug comes in the form of a powder that is converted into a solution before being administered. The main purpose of this research is to determine how well this new treatment works and how safe it is for patients who have already received previous treatments for their gastrointestinal cancer.

This is a combined Phase 1b/2 study, which means it will assess both the safety and effectiveness of the treatment. The study is “open-label,” which means all participants will know which treatment they are receiving. Some participants will receive different doses of the medication to help determine which amount works best while maintaining safety. The study will include multiple medical centers to ensure a thorough evaluation of the treatment.